61 search results for: symptoms

Most Burdensome <b>Symptoms</b> Rated by PN Patients

expert video

Most Burdensome Symptoms Rated by PN Patients

1 min

Dermatology

Dr. Chovatiya discusses the impact of pruritus on patients with PN.

expert video

Diagnosis and Clinical Manifestations of Bullous Pemphigoid

2 min

Dermatology

Join Dr. Meijer as he highlights the signs and symptoms of bullous pemphigoid, and the importance of accurate and prompt diagnosis.

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

10 min

Rhinology

Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.

interactivity

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min

Dermatology

This interactive tool allows you to explore the global burden of AD in pediatric patients <12 years from the PEDISTAD Study.

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

expert video

Skin Barrier Dysfunction in AD

4 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

interactivity

Guideline-Based Diagnosis of Atopic Dermatitis

15 min

Dermatology

Explore 3 interactive patient cases to learn more about the signs, symptoms, and burden of atopic dermatitis. Diagnose the patients based on a variety of cases and presentations based on American Academy of Dermatology (AAD) criteria and assess their disease severity

expert video

Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid

12 min

Dermatology

Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms

expert video

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

15 min

Dermatology

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region